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Immortalized rat proximal tubule cells produce membrane bound and
soluble megalin. Megalin (gp330), a glycoprotein receptor found on renal
proximal tubule cells and several other epithelial cells, is deduced to be a
type I integral membrane protein, but may also exist as a cell surface form
lacking a cytoplasmic domain. Furthermore, soluble megalin products
have been detected in urine, and in culture medium of a rat yolk sac
carcinoma cell line, combined with receptor associated protein (RAP).
Permanent renal cell lines expressing megalin were unavailable until the
recent description of two immortalized rat proximal tubule cell lines
(IRPTC). The present study demonstrated megalin on IRPTC surface by
immunofluorescence, without surface staining for RAP, which was, how-
ever, readily detected within cells. Antibodies to ectodomain megalin
epitopes immunoprecipitated megalin products both from cell lysates and
culture medium, whereas antibodies to cytoplasmic domain epitopes
precipitated megalin only from lysates. Western blots showed two major
megalin products in medium, a prominent band at ;200 kDa, and a
fainter band above 400 kDa, slightly below intact megalin in cell lysates.
Anti-receptor associated protein antibodies immunoprecipitated megalin
from IRPTC lysates, but not from media. We propose that portions of
megalin are spontaneously produced by IRPTC, probably either by
cleavage in the ectodomain or release of forms lacking a cytoplasmic
domain.
Megalin (also known as gp330 or gp600) is a large glycoprotein
and one of the most abundant membrane proteins in the renal
proximal tubule [1–3]. It is the major target antigen in Heymann
nephritis, a model of human membranous glomerulonephritis
[3–7]. Megalin is located mainly in the regions of clathrin-coated
pits, and to a lesser extent on microvilli, at the apical surface of
renal proximal tubule cells, as well as on podocytes (in the rat) and
several other epithelial cells, including epididymal cells, type II
pneumocytes and yolk sac cells [8–13]. Megalin is deduced to be
a type I integral membrane protein and a member of the low
density lipoprotein receptor gene family [14–16], which includes
the low-density lipoprotein (LDL) receptor [17], the LDL recep-
tor-related protein/a2-macroglobulin receptor (LRP/a2MR) [18,
19] and the very low density lipoprotein (VLDL) receptor [20, 21].
Megalin has been shown to bind multiple ligands, mainly in assays
performed in vitro, including apoE enriched VLDL [22], low
density lipoproteins [23], lipoprotein lipase [24], plasminogen
[25], plasminogen activator inhibitor type 1 complexes (uPA-
PAI-1) [22, 26], lactoferrin [22], clusterin (apolipoprotein J)
[27–29], aprotinin [30], transcobalamin-vitamin-B12 complexes
[31], and extracellular matrix components [32]. Recently, megalin
was also found to bind nephrotoxic polybasic antibiotics, such as
aminoglycosides and polymyxin B [33]. Furthermore, megalin is a
calcium binding protein, and Ca21 is required for ligand binding,
suggesting that it may be involved in calcium sensing or in tubular
absorption of Ca21 filtered by the glomerulus [16, 34]. Many of
the ligands of megalin are also ligands of low-density lipoprotein
receptor-related protein (LRP) [12, 22, 30, 35].
Shortly after its biosynthesis, megalin forms a stable complex in
the rough endoplasmic reticulum (RER) with a 39 to 44 kDa
protein known as the receptor associated protein [5, 36–38]. The
receptor associated protein (RAP) is a resident RER protein,
which apparently acts as a molecular chaperone to assist in the
processing, intracellular trafficking and targeting of megalin [39]
and LRP [40–42]. In vitro, RAP can block binding of all known
ligands to megalin or LRP [43], but it may not serve to control
ligand binding to cells in vivo, since little or no RAP has been
detected on the cell surface [5, 44–46]. Rather, it appears that
because LRP and megalin are complexed with RAP within the
RER, physiologic ligands that are also in the RER on route to
export are prevented from premature binding to the receptors,
which would lead to their degradation [42].
The physiologic functions of megalin are not entirely under-
stood, but compelling evidence that it can mediate endocytosis of
various ligands has been obtained using cultured cells [28, 30, 34,
50], as well as through in vivo experiments in which locally
perfused ligands were endocytosed by renal tubules or epididymal
cells [26, 27, 30]. Uptake was inhibited by RAP and/or anti-
megalin antibodies in these studies. Physiologic ligands of megalin
probably vary from one organ to another, depending on the
composition of the fluids to which it is exposed.
Certain evidence indicates that megalin may exist in two forms
on proximal tubule cells [47]. One postulated form is restricted to
coated pit regions and is reactive both with antibodies against
ectodomain and cytoplasmic domain epitopes, as expected of a
Type I integral membrane protein. The other postulated form is
present over the microvilli and lacks reactivity with antibodies
against the cytoplasmic domain [47], suggesting it is a truncated
form of megalin. The functional significance of the two postulated
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forms is unknown, but it is possible that the “microvillar form”
may be shed, either spontaneously, or following interaction with
antibodies or ligands. There is evidence that soluble as well as
membrane vesicle bound forms of megalin are normally present in
urine [24, 48, 49], but it is not known whether or not urinary
megalin is derived mainly from the “microvillar form.”
Various aspects of megalin physiology, including its ligand
binding potential, and the nature of soluble megalin products can
be studied using cultured cells. Primary cultures of renal tubular
cells have been used, but such cells often cease to express certain
proteins, including megalin, after several passages. Until recently,
the only available permanent cell lines regularly expressing mega-
lin were of non-renal origin [39, 50, 51]. These cell lines also
express LRP protein, which, as noted above, binds many of the
same ligands as megalin [22]. Orlando and Farquhar reported that
a rat yolk sac carcinoma cell line (L2) expresses megalin and RAP
as a complex on the surface [39]. Furthermore, they found a
soluble form of megalin, combined with RAP, in the culture
medium [39]. In another study Moestrup et al [30] confirmed
abundant production of megalin by L2 cells, but also found small
amounts of LRP in L2 cells by immunoblotting, and a low level of
uptake of a2-macroglobulin (a2m)-chymotrypsin, which is a li-
gand for LRP, but not for megalin.
In the present study we investigated the expression and release
of soluble megalin products and RAP in cultured rat renal tubule
cells, using two recently developed immortalized cell lines
(IRPTC) [52–54], and compared the findings with those in L2
cells.
METHODS
Cell lines
Two immortalized rat proximal tubule cell lines (IRPTC) were
established, as previously described [53, 54]. One cell line, re-
ferred to as origin defective, was obtained by transfection with
origin-defective SV40 DNA mutant 6-1 in pMK16 (20 mg/culture
dish); this cell line appears transformed at all times at 37°C. A
second cell line, referred to as temperature sensitive, was devel-
oped by exposure of primary cultures to SV40 tsA virus 29; this
line was studied both at 34°C (the permissive temperature) with
cells of transformed phenotype and at 41°C, at which temperature
the cells have morphology of nontransformed cells. Both cell lines
were used in the present studies for several reasons. Firstly, the
fact that the temperature sensitive cell line has a non-transformed
phenotype at 41°C is helpful in investigating “normal physiology.”
Secondly, the origin-defective cell line grows rapidly and is
particularly useful for studies in which many cells are needed.
Both cell lines were maintained in modified Dulbecco’s Eagle’s
medium (DMEM). The medium was at pH 7.5 and was supple-
mented with 3.8 mg/ml NaHCO3, 25 mM HEPES (N-2-hydroxy-
ethylpiperazine-N9-2-ethanesulfonic acid) buffer, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, 0.1 mM sodium pyruvate, 0.01 mM
nonessential amino acids and 5% fetal bovine serum (FBS). In
certain experiments, as noted, cells were placed overnight in
serum-free DMEM. The origin defective cell line was maintained
at 37°C, 5% CO2, with media changes every two to three days. The
temperature cell line was maintained at 34°C or 41°C as noted,
with 5% CO2.
The rat yolk sac carcinoma cell line (L2) [55] was kindly
provided by Dr. John Kanalas (University of Texas Health
Sciences Center, San Antonio, TX, USA), and primary cultures of
rat mesangial cells [56] were kindly provided by Dr. Joseph
Bonventre (Massachusetts General Hospital, Boston, MA, USA).
Antibodies
Megalin. Three previously characterized anti-megalin antibod-
ies were used: (1) a monoclonal antibody (1H2), which recognizes
epitopes of the extracellular domain in the second cluster of
ligand binding repeats [7, 47]; (2) a rabbit polyclonal anti-megalin
antiserum (A55), which reacts with multiple epitopes, mainly in
the ectodomain [57] and (3) a rabbit antiserum (Rb3) prepared
against a peptide sequence of the cytoplasmic tail [47]. The
anti-cytoplasmic (Rb3) antibody recognizes intact megalin but
fails to stain ectodomain epitopes, as demonstrated by immuno-
gold studies [47]. These antibodies have been extensively charac-
terized, and none cross-react with LRP.
Low density lipoprotein receptor-related protein (LRP). Affinity
purified IgG was prepared from rabbit anti-human LRP anti-
serum, kindly provided by Dr. Dudley Strickland (American Red
Cross, Rockville, MD, USA). The antibodies were previously
shown to react with rat LRP by immunofluorescence, without
reactivity against RAP, the LDL receptor or megalin [10, 58].
Receptor associated protein (RAP). A rabbit antiserum against a
rat RAP-glutathione transferase (GST) fusion protein was kindly
provided by Dr. Joachim Herz (University of Texas, Southern
Medical Center, Dallas, TX, USA). This antiserum has been
shown by Western blot analysis to react with a protein of about 44
kDa in most preparations of megalin [59]. We used an additional
rabbit antiserum against the RAP fusion protein, prepared as
previously described [10].
Immunofluorescence
Cells were grown to 95% confluence in 35 mm2 petri dishes on
12 mm2 coverslips in DMEM. To detect reactivity with ectodo-
main surface proteins, unfixed, non-permeabilized cells were
incubated with the monoclonal anti-megalin antibody, 1H2, or
with rabbit antibodies to LRP or RAP at 4°C for two hours, and
then fixed in 4% paraformaldehyde. To detect intracellular reac-
tivity, cells were first fixed in 4% paraformaldehyde, permeabil-
ized with 0.1% triton X-100 in PBS, blocked with PBS containing
0.5% bovine serum albumin (BSA) and then incubated with the
rabbit antibody (Rb3) to the cytoplasmic domain of megalin, to
RAP, or to LRP at 4°C for two hours. Non-immune rabbit serum
was used as a control. Additional controls were carried out with
FITC-coupled secondary antibodies alone. Treated cells were
washed in PBS and incubated for one hour, either with FITC-
labeled goat anti-rabbit IgG antibody (Vector Labs, Burlingame,
CA, USA) (20 mg/ml in PBS) or FITC-conjugated goat anti-
mouse IgG antiserum (Sigma, St. Louis, MO, USA). Coverslips
were then applied to slides in 50% glycerol in 0.2 M Tris-HCl, pH
8.0, containing 2% n-propyl gallate to retard quenching of the
fluorescence signal. The slides were examined using a Nikon FXA
photomicroscope and photographed with Kodak Tmax 400 film,
push-processed to 1600 ASA.
Preparation of cell lysates and Western blot analysis
Cells from both temperature sensitive and origin defective
IRPTC lines, L2 cells and mesangial cells were cultured in T-75
flasks, washed twice with cold PBS, in order to remove culture
medium, and then scraped from the flask wall using a rubber
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policeman. Approximately 1 3 106 cells were dispersed, collected
in 1.5 ml of RIPA detergent buffer (150 mM NaCl, 1% NP-40,
0.5% DOC, 0.1% SDS, 50 mM Tris, pH 7.5) containing 1 mM
PMSF and 5 mM EDTA [60]. The cells were left on ice for 30
minutes with occasional mixing. The lysate was microcentrifuged
at 14,000 3 g for 10 minutes at 4°C, and the supernatant was
heated at 95°C for five minutes in Laemmli buffer, separated by
SDS-PAGE under non-reducing conditions on a 4 to 12% gradi-
ent gel and transferred to nitrocellulose using the wet transfer
method (50 mM Tris, 380 mM glycine, 0.1% SDS) for two hours at
80 Volts (Biorad). The nitrocellulose membrane was placed in
blocking buffer (10 mM Tris-HCl, 150 mM NaC1, 0.05% Tween 20,
3.0% BSA and 0.02% sodium azide) followed by incubation with
the rabbit antibodies to megalin (Rb3 and A55), as well as to RAP
or LRP. The nitrocellulose was then washed in several changes of
blocking buffer, incubated for 60 minutes with blocking buffer
that contained 10 mg/ml goat anti-rabbit IgG conjugated to
alkaline phosphatase (Vector Labs). Alkaline phosphatase activity
was detected with BCIP/NBT Phosphate Substrate System
(Kirkegaard & Perry Lab., Inc., Gaithersburg, MD, USA).
Immunoabsorption of megalin and receptor associated protein
from culture media and cell lysates
The cells were placed in serum free medium (DMEM) for 24
hours before use. Twenty milliliters of serum free media from the
origin defective renal cells, and L2 cells were incubated with the
rabbit anti-megalin antiserum (A55) or rabbit anti-cytoplasmic
peptide antiserum (Rb3) covalently coupled to protein A sepha-
rose beads, which were then washed three times with RIPA
buffer, placed in sample buffer and run in a 4 to 12% gradient gel
(Biorad) under reducing conditions. Proteins were transferred to
nitrocellulose. The blots were incubated with the monoclonal
anti-megalin antibody (1H2), which was detected by horseradish
peroxidase conjugated sheep anti-mouse IgG.
To determine if RAP was complexed with megalin found in the
medium, 20 ml of medium from origin defective cells, L2 cells and
Fig. 1. The left panel shows non-permeabilized,
immortalized rat proximal tubule cell lines
(IRPTC) that were incubated at 4°C with the
monoclonal anti-megalin antibody (1H2),
followed by FITC labeled goat anti-mouse IgG.
The right panel shows permeabilized IRPTC
that were incubated with the rabbit antiserum
against the megalin cytoplasmic domain
followed by FITC labeled goat anti-rabbit IgG:
(a and d) temperature sensitive cells at 34°C;
(b and e) origin-defective cells; (c and f)
temperature sensitive cells at 41°C. Punctate
granular staining is seen in all cells, consistent
with coated pit localization. Bar 5 20 mm.
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cell lysates (as positive controls), obtained as above, were incu-
bated with rabbit antibodies to megalin (A55) and to RAP
coupled to protein A sepharose beads and treated as above.
Following transfer of proteins to nitrocellulose, the blots were
incubated with 1H2, to detect megalin products.
RESULTS
Expression of megalin, LRP and RAP by immortalized renal
proximal tubule cells
By immunofluorescence microscopy, both renal cell lines (ori-
gin defective and temperature sensitive) showed bright, punctate
staining following incubation of non-permeabilized cells at 4°C
with the monoclonal anti-megalin antibody (1H2) or incubation of
permeabilized cells with the rabbit antibody against the cytoplas-
mic domain (Rb3) (Fig. 1).
The results of Western blot analysis of IRPTC lysates for
megalin are shown in Figure 2. Both the rabbit anti-megalin
ectodomain antiserum (A55) and the rabbit anti-cytoplasmic
peptide megalin antiserum (Rb3) recognized a major band, above
400 kDa. Some additional bands were seen, which were even more
prominent, with purified megalin than with lysates. Megalin is
known to undergo spontaneous degradation into smaller frag-
ments [1, 2].
Incubation of non-permeabilized cells at 4°C with rabbit anti-
bodies to RAP or LRP did not produce staining, thus failing to
provide evidence of cell surface expression of these proteins. In
contrast, incubation of permeabilized cells with anti-RAP (Fig. 3)
resulted in intense intracellular staining; incubation with anti-
LRP antibodies resulted in faint intracellular staining (data not
shown). Furthermore, Western blot analysis of lysates of origin-
defective IRPTC with anti-LRP antibodies revealed a very faintly
stained band at about 600 kDa (Fig. 4 lane 3).
Expression of megalin, LRP and RAP by rat yolk sac carcinoma
cells. Incubation of non-permeabilized L2 cells at 4°C with rabbit
antibodies to megalin (A55) or LRP resulted in punctate staining
(Fig. 5 A, B), indicating cell surface expression. Stains for RAP in
nonpermeabilized cells were inconclusive, owing to high back-
ground obtained with normal rabbit serum. With permeabilized
cells, bright intracellular staining for RAP and LRP was seen (Fig.
5 C, D). In addition, Western blot analysis of L2 cell lysates with
anti-LRP antibodies revealed a moderately intense band at about
600 kDa (Fig. 4, lane 1).
Western blot analysis of megalin products and RAP in culture
media of IRPTC and L2 cells
IRPTC. Proteins immunoprecipitated from the medium of
IRPTC by the rabbit anti-megalin antibodies (A55 and Rb3) or by
anti-RAP antibodies were analyzed in Western blots and com-
pared with findings in cell lysates (Fig. 6). The lysates immuno-
precipitated by the rabbit antibody against megalin ectodomain
epitopes (A55) contained broad overlapping bands extending
from about 200 kDa to about 600 kDa (Fig. 6, lane 2). Two
prominent megalin bands were identified in the medium, a major
band at about 200 kDa and a less intense band at a higher
molecular mass (above 400 kDa), which was slightly below the
highest region of megalin identified in cell lysates (Fig. 6, lane 6);
in addition, several faint bands were seen. The anticytoplasmic
peptide megalin antibody (Rb3) immunoprecipitated high molec-
ular weight megalin from lysates (lane 3) but no products were
precipitated from medium (lane 7).
The anti-RAP antibody did not immunoprecipitate any prod-
ucts from IRPTC culture medium. However, the anti-RAP anti-
bodies precipitated a large protein (. 400 kDa) from IRPTC
lysates that was recognized by the monoclonal anti-megalin
antibody 1H2, indicating that RAP had been complexed with
megalin within cells (Fig. 6, lane 4); this was despite the fact that
the product recognized on the gels had dissociated from RAP
under the conditions used. That megalin was not precipitated
from the culture medium by anti-RAP antibodies (Fig. 6, lane 8)
indicates that the soluble megalin product was not complexed with
RAP.
L2 cells. Lysates and medium of L2 cells were incubated with
rabbit antibodies to megalin ectodomain (A55) or cytoplasmic
domain epitopes (Rb3), or rabbit anti RAP antibodies conjugated
to sepharose beads, and the immunoabsorbed proteins were
analyzed in Western blots as shown in Figure 7. As with IRPTC,
both anti-megalin antibodies immunoprecipitated proteins from
lysates, whereas only the antibodies against ectodomain epitopes
immunoprecipitated megalin from the medium, including a prom-
inent product at about 200 kDa. However, in contrast with the
results obtained with IRPTC, the megalin present in the medium
of L2 cells was complexed with RAP.
DISCUSSION
As previously reported [52–54], two IRPTC lines (temperature
sensitive and origin defective) were found to express megalin on
the cell surface, which was detected by immunofluorescence in a
punctate pattern consistent with coated pit localization. Neither
RAP nor LRP was detected on the cell surface, although both
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Fig. 2. Immortalized rat proximal tubule cell line (IRPTC) lysates and
purified megalin were subjected to SDS-PAGE, under nonreducing con-
ditions and the proteins were transferred to nitrocellulose. The left panel
shows staining produced by the rabbit anti-megalin antiserum (A55): lane
1, temperature sensitive IRPTC at 34°C; lane 2, origin-defective IRPTC;
lane 3, temperature sensitive IRPTC at 41°C; lane 4, immunoaffinity
purified megalin. The right panel shows the same cell lysates that were
incubated with the rabbit anti-cytoplasmic megalin peptide antiserum
(Rb3). Both antibodies recognize a major band, above 400 kDa. A55
recognizes additional smaller bands in the IRPTC 41°C lysates, and even
more in purified megalin. Molecular weight markers are on the left.
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proteins were found by immunofluorescence within permeabilized
cells and were also detected in cell lysates by Western blot
analysis. However, anti-LRP antibodies produced only a very faint
band, indicating a low level of expression. Low density lipoprotein
receptor-related protein (LRP) has not been detected in proximal
tubule cells in renal tissue sections by immunofluorescence [10],
and its presence in IRPTC may, therefore, not reflect its presence
in vivo. It is possible that the lack of surface staining is the result
of improper processing of LRP in IRPTC. In this regard, Herz et
al [61] have reported that a small amount of LRP in a cultured cell
line remain in a 600 kDa (unprocessed) form and does not reach
the cell surface. It is also possible that some LRP is present on the
surface, but below the level of detection. In any case, our findings
suggest that the IRPTC will probably not bind ligands via LRP,
which should facilitate their use in studies of megalin ligands. In
contrast, we found that the rat yolk sac carcinoma cells (L2)
expressed abundant surface LRP, as well as megalin. Our obser-
vations differ from those of Moestrup et al [30], who reported that
a monoclonal anti-LRP antibody failed to stain L2 cells, although
a faint band was produced by anti-LRP antibodies in Western
blots of cell lysates. The divergent results may stem from differ-
ences in techniques used to detect LRP and differences in culture
conditions. In any case, our results indicate that L2 cells may bind
ligands to LRP as well as to megalin, although probably less avidly
than to megalin [30].
We were unable to detect RAP on the surface of IRPTC. In
contrast, in studies on L2 cells Orlando and Farquhar detected
surface RAP in association with megalin by 3H leucine labeling of
cells and immunoprecipitation of surface proteins [39]. Further-
more, we found RAP complexed with megalin in the medium of
L2 cells but not IRPTC. These results suggest that RAP may be
processed in L2 cells by a pathway different from that in IRPTC,
which leads to surface expression on L2 cells. Nevertheless, some
of the RAP found on surface of L2 cells in culture may be
artifactual, resulting from RAP release from damaged or dead
cells. This possibility is suggested by an immunohistochemical
study of rat renal tissue, in which we showed that intracellular
RAP was released during preparation of frozen tissue sections,
following which it combined with megalin on the cell surface [44].
In contrast, in aldehyde fixed tissue, RAP was found almost
exclusively within the rough endoplasmic reticulum (RER), re-
flecting its normal location. As noted earlier, there is compelling
evidence that RAP is a resident RER protein, which probably
functions to facilitate proper folding of megalin and LRP and
prevent premature binding of ligands destined for export [42].
In vivo evidence for the presence of RAP on the cell surface has
been obtained by the demonstration that the intravenous injection
of rabbit anti-RAP antibodies to normal rats rapidly results in the
formation of glomerular deposits, presumably due to shedding of
immune complexes formed on podocytes [4, 5, 62, 63]. However,
evidence has recently been presented that RAP and megalin
possess shared epitopes [64], suggesting the possibility that the
injected anti-RAP antibodies react with megalin on podocytes,
rather than with RAP itself. Nevertheless, we found no evidence
that the rabbit anti-RAP antibodies we used in the present study
recognized megalin, since they failed to produce surface staining
of non-permeabilized IRPTC, which stained intensely for mega-
lin.
We found megalin not only on the surface and in lysates of the
IRPTC and L2 cells, but also in the culture medium. However,
whereas cell bound megalin reacted both with antibodies to the
ectoplasmic and cytoplasmic domain, the material in the media
reacted only with antibodies to ectodomain epitopes. Two general
Fig. 3. Immortalized rat proximal tubule cell lines (IRPTC) were permeabilized and incubated with rabbit anti-receptor associated protein (RAP)
antibodies and then with FITC labeled goat anti-rabbit IgG. (a) Temperature sensitive cells at 34°C; (b) origin-defective cells; (c) temperature sensitive
cells at 41°C. Diffuse, granular intracellular staining is seen, consistent with localization in the rough endoplasmic reticulum (RER). Bar 5 15 mm.
600
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Fig. 4. Western blot analysis for low-density lipoprotein receptor-related
protein (LRP) in lysates of rat yolk sac carcinoma (L2) cells (lane 1), rat
mesangial cells as positive control (lane 2) and immortalized rat proximal
tubule cell lines (IRPTC; lane 3). Rabbit antibodies to LRP produced
staining of a band at about 600 kDa, consistent with the molecular weight
of LRP in all lysates. Staining was most intense in mesangial cell lysates
and was very faint in IRPTC.
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explanations can be considered to account for these findings. One,
the cells may produce a form of megalin lacking a cytoplasmic
domain, which is spontaneously released into the medium [47].
Second, a portion of the ectodomain may be released from the
intact integral membrane protein through proteolytic cleavage of
megalin, as has been postulated to occur in Heymann nephritis,
where portions of the ectodomain are apparently shed from
podocytes following interaction with anti-ectodomain megalin
antibodies [7, 47, 62].
While it is conceivable that release of megalin products could
result from cell injury, neither LDH [52–54] nor RAP were found
in media from IRPTC lines, arguing against the release of
intracellular proteins from damaged or dead cells. Thus, it is most
likely that megalin was, in fact, released from intact cells. Fur-
thermore, soluble megalin products have been reported both in
normal urine [24, 48, 49] and in cerebrospinal fluid [ 13],
suggesting that megalin products may indeed be released physio-
logically.
In previous studies on L2 cells, Orlando and Farquhar have
described soluble forms of gp330 released into the medium, with
a prominent fragment at about 220 kDa [39]. In the present study,
we found a prominent megalin product at about 200 kDa in the
media of both L2 cells and IRPTC. These results suggest that the
same roughly 200 kDa megalin fragment may be released from
different cell types. Orlando, Kerjaschki and Farquhar suggested
[6] that the soluble form of megalin may be generated by
proteolysis at a putative cleavage site (RLRR) for furin [15].
However, this is located at residues 3245-3248 [15], and cleavage
at that site would yield a much larger fragment than we have
observed.
Birk et al [48] and Kounnas et al [24] have demonstrated small
amounts of megalin products in normal human urine. Further, it
has been shown that immunization of rats with megalin obtained
from normal human urine can induce Heymann nephritis [49].
These observations, combined with the findings in cultured cells,
suggest that release of megalin products is a physiologic process.
In addition, however, it appears that megalin release can be
increased by anti-megalin antibodies as in Heymann nephritis, or
Fig. 5. Non-permeabilized rat yolk sac carcinoma (L2) cells (a and b) were incubated at 4°C with rabbit antibodies (A55) to megalin (a) or to
low-density lipoprotein receptor-related protein (LRP; b), and then with FITC labeled goat anti-rabbit IgG. There is punctate, surface staining with both
antibodies. Permeabilized L2 cells (c and d) were prepared by incubation with 4% paraformaldehyde and then with 0.1% Triton X100, following which
they were incubated with rabbit antibodies to RAP (c) or LRP (d), and then with FITC-labeled goat anti-rabbit IgG. There is diffuse cytoplasmic staining
for receptor associated protein (RAP). The LRP also shows intracellular staining, which is concentrated over nuclei; in addition there is peripheral,
punctate staining. Bar 5 20 mm.
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in other conditions with proximal tubule cell damage [65]. Simi-
larly, other receptors have been shown to be released from cells
following interactions with antibodies [66].
The functional properties of the soluble megalin products are
unknown. However, the finding that soluble megalin released
from IRPTC or L2 cells is recognized by the monoclonal antibody
1H2 indicates that it contains ligand binding domains, in the
second cluster of repeats [7]. Further studies are needed to
determine ligand binding potential of the soluble megalin prod-
ucts.
Soluble forms of various cell surface integral membrane recep-
tors have been described, including polypeptide hormone and
cytokine receptors, and the asialoglycoprotein receptor [67–69].
Some soluble forms are produced by proteolytic cleavage of the
membrane receptors, whereas others are secretory products [68].
In the case of the asialoglycoprotein receptor a soluble product
has been shown to be produced from an alternatively spliced
variant of the H2 subunit, which is cleaved after insertion into the
ER membrane to release a 35 kDa fragment that is efficiently
secreted from Hep G2 cells [69]. In addition to truly soluble
products, some cell receptors are released in association with cell
membrane fragments [70], including some of the megalin found in
the urine [48]. Although the physiologic significance of most
soluble or membrane bound released receptors is not entirely
understood, it is known that many have ligand binding capacity.
Possible modes of action include inhibition of interaction between
ligands and cell bound receptors, and transport of ligands. In
addition, the soluble receptors may have unexpected functions.
Thus, a soluble form of the LDL receptor has been shown to
possess antiviral activity (against VSV), not attributable to pre-
vention of binding of the virus to cell bound LDL receptor, which
does not serve as the receptor for the virus [71].
In summary, the two IRPTC lines used in the present studies
provide a source of renal proximal tubule cells that express
surface megalin without co-expression of surface LRP. The cells
should thus be useful for identification of ligand binding to gp330
without the confounding problem of binding to LRP, which is
known to recognize many of the same ligands as megalin. The
release of a soluble form of megalin into medium may reflect a
physiological process that can be further investigated with these
cell lines.
ACKNOWLEDGMENTS
These studies were supported by National Heart, Lung and Blood
Institute Grants HL-40210, HL-48455 (to J.R.I.) and National Institute of
Diabetes and Digestive and Kidney Diseases, DK-46301 (to R.T.M.). This
study was presented in part at the American Society for Nephrology in
200
1 2 3 4 5 6 7 8
118
86
52
34
29
19
7.5
Fig. 6. Serum free medium and cell lysates from cultures of the origin-
defective immortalized rat proximal tubule cell lines (IRPTC) were
incubated with rabbit anti-megalin serum (A55), the anti-cytoplasmic
peptide serum (Rb3), rabbit anti-receptor associated protein (RAP)
antibodies or normal rabbit serum coupled to sepharose beads. The
immunoabsorbed proteins were separated by SDS-PAGE under reducing
conditions and transferred to nitrocellulose and studied for reactivity with
the monoclonal antibody to megalin (1H2). Lanes 1 through 4 represent
lysates, and 5 through 8 medium. Incubation with normal rabbit serum did
not precipitate megalin (lanes 1 and 5). Incubation with A55 immunopre-
cipitated megalin products both from lysates (lane 2) and medium (lane
6); the megalin in the lysates migrated as coalescing bands in a broad area,
above 200 kDa, whereas the proteins in the medium migrated mainly as
two discrete bands, one at about 200 kDa and the other considerably
higher, but below the highest region in the lysates. Rb3 precipitated high
molecular weight megalin products from the lysates (lane 3), but not from
the medium (lane 7). The anti-RAP antibodies immunoprecipitated
megalin (. 400 kDa) from lysates (representing RAP complexed with
megalin; lane 4), but not from the medium (lane 8). The faint bands at
about 52 kDa represent the heavy chain of rabbit IgG.
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Fig. 7. Rat yolk sac carcinoma cell line (L2) lysates and culture medium
were incubated with normal rabbit serum, rabbit antimegalin antibodies
(A55), rabbit anticytoplasmic peptide antibodies (Rb3) or rabbit anti-
receptor associated protein (RAP) antibodies coupled to sepharose beads.
The immunoprecipitated proteins were separated by SDS-PAGE, under
reducing conditions, transferred to nitrocellulose and examined for mega-
lin products, identified by 1H2. Incubation with normal rabbit serum
(lanes 1 and 5) failed to precipitate megalin. The A55 immunoprecipitated
megalin was produced both from lysates (lane 2) and medium (lane 6).
The megalin products in the lysates and in the medium were present over
a large range of molecular weights, but in the medium a prominent area
of staining was seen at about 200 kDa. Rb3 immunoprecipitated megalin
products from lysates (lane 3) but not the medium (lane 7). Rabbit
anti-RAP antibodies immunoprecipitated megalin both from lysates (lane
4) and medium (lane 8), indicating that RAP was complexed with megalin;
the material in the medium appeared mainly in a roughly 200 kDa band,
with additional fainter higher molecular weight bands. The faint bands at
about 52 kDa represent the heavy chain of rabbit IgG.
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APPENDIX
Abbreviations used in this article are: a2m, a2-macroglobulin; BSA,
bovine serum albumin; DMEM, Dulbecco’s modified Eagle’s medium;
FBS, fetal bovine serum; GST, glutathione transferase; HEPES, N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid; IRPTC, immortalized
rat proximal tubule cell lines; L2, rat yolk sac carcinoma cell line; LDL,
low density lipoprotein; LRP, low density lipoprotein receptor-related
protein; LRP/a2MR, low density lipoprotein receptor-related protein/a2-
macroglobulin receptor; RAP, receptor asociated protein; RER, rough
endoplasmic reticulum; uPA-PAI-1, plasminogen activator inhibitor type
1 complexes; VLDL, very-low density lipoprotein.
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